76 percent of patients on oral JAK1/JAK2 inhibitor plus DMARDS achieve ACR20 response at week 12
Baricitinib demonstrates dose-dependent efficacy in active RA
2012-06-08
(Press-News.org) Berlin, Germany, June 8 2012: Data from a Phase IIb study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, show that 76% of patients with active rheumatoid arthritis (RA) receiving either 4mg or 8mg of baricitinib, an oral JAK1/JAK2 inhibitor, plus stable methotrexate (MTX) achieved ACR20* response compared with 41% of placebo-treated patients (p≤0.001) at 12 weeks. The 4mg and 8mg doses of baricitinib demonstrated statistical superiority to placebo in all clinical outcomes measured, including ACR20/50/70*, DAS28**-CRP and DAS28-CRP END
ELSE PRESS RELEASES FROM THIS DATE:
Novel brain imaging technique explains why concussions affect people differently
2012-06-08
June 8, 2012 — (Bronx, NY) — Patients vary widely in their response to concussion, but scientists haven't understood why. Now, using a new technique for analyzing data from brain imaging studies, researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that concussion victims have unique spatial patterns of brain abnormalities that change over time.
The new technique could eventually help in assessing concussion patients, predicting which head injuries are likely to have long-lasting neurological consequences, ...
Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis
2012-06-08
Berlin, Germany, June 8 2012: A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs.
This American study, the largest of its kind, followed 2,811 treatment naïve patients initiated onto anti-TNF therapy. Of the study group, 19% (n=521) were smokers and 81% (n=2,290) were non-smokers. Smokers had significantly higher scores on the Clinical Disease ...
Lung changes are present in nearly half of ACPA positive RA patients at disease onset
2012-06-08
Berlin, Germany, June 8 2012: A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that lung changes in association with anti-citrullinated protein autoantibody (ACPA) status are a primary manifestation of rheumatoid arthritis (RA).
Study findings show that 51% of RA patients (n=105) had identifiable lung changes (as measured by high resolution computer tomography [HRCT]) as compared to 28% of healthy controls (n=43). In addition, ACPA presence – but not smoking status – was associated with HRCT changes. This ...
Obesity negatively predicts minimal disease activity achievement in patients with PSA
2012-06-08
Berlin, Germany, June 8 2012: According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment and adhere to a hypocaloric diet have a significantly greater chance of achieving minimal disease activity (MDA, an important measure of disease activity) at six months compared to those on a standard diet.
The results of an Italian study of 138 obese PsA patients demonstrated that those who achieved a ≥10% weight ...
Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo
2012-06-08
Berlin, Germany, June 8 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than twice as likely to achieve the study's primary endpoint, ACR20* at 24 weeks, than those treated with placebo (49.5% vs 22.8%). 42.4% of patients treated with UST 45mg were also more likely to achieve ACR20 at 24 weeks compared to placebo.
Significant improvements were also seen with UST 45mg and 90mg in ACR50* (24.9% ...
Early menopause predicts a milder form of rheumatoid arthritis
2012-06-08
Berlin, Germany, June 8 2012 : A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that early menopause predicts a milder form of rheumatoid arthritis (RA). New insights on factors influencing RA are good news for sufferers of the chronic inflammatory disease that currently affects over 2 million women in Europe. 1,2
The study, based on 134 incident RA cases, found that patients aged over 45 years with a history of early menopause were 50% less likely to develop severe RA (16% versus 35%) and more likely to develop ...
Rabbit risk score can help rheumatologists identify patients at high risk of infection
2012-06-08
Berlin, Germany, June 8 2012: Results of a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, suggest that the newly developed RABBIT Risk Score, which calculates the risk of serious infections in patients with rheumatoid arthritis (RA) who are treated with anti-tumour necrosis factor drugs (anti-TNFs) or conventional disease modifying anti-rheumatic drugs (DMARDs) is a valid and effective tool for rheumatologists to predict risk of serious infection.
The German study used data from 2,603 patients enrolled in the RABBIT ...
13.7 million young adults stayed on or joined their parents' health plans in 2011
2012-06-08
June 8, 2012, New York, NY—In 2011, 13.7 million young adults ages 19 to 25 stayed on or joined their parents' health plans, including 6.6 million who would likely not have been able to do so before passage of the Affordable Care Act, according to a new Commonwealth Fund report.
However, not all young adults have parents with health plans they can join, and many still experience gaps in coverage and face medical bill problems and medical debt. Nearly two of five (39%) young adults ages 19 to 29 went without health insurance at some time in 2011, and more than one-third ...
Parcel2Go Helping Small Businesses to Beat Royal Mail Price Increase
2012-06-08
Small firms feeling the squeeze following the Royal Mail's decision to increase the price of first and second class stamps at the end of last month are being offered a helping hand by Bolton-based online parcel delivery firm Parcel2Go.
The company says businesses and individuals can try to beat the Royal Mail price increase by becoming Parcel2Go users and benefiting from the vast range of reliable and cost-effective UK express delivery solutions available through the website.
With just a few clicks of a mouse, customers can order delivery services from some of the ...
King Jackpot Makes Playing No Deposit Bingo a Breeze
2012-06-08
Any experienced bingo player can tell you that one of the keys to success in playing bingo online is choosing the right bingo website. Many bingo websites are all talk and no show, or do not give players the generous offers that they desire and deserve. One feature on bingo websites that every new player should look out for is no deposit required bingo.
This means that when players register, they are given free cash to be used towards trying bingo games on the website, without spending a penny of their own money! While players cannot withdraw this cash for personal ...
LAST 30 PRESS RELEASES:
To reach net-zero, reverse current policy and protect largest trees in Amazon, urge scientists
Double trouble: Tobacco use and Long COVID
Eating a plant-forward diet is good for your kidneys
Elucidating liquid-liquid phase separation under non-equilibrium conditions
Fecal microbiome and bile acid profiles differ in preterm infants with parenteral nutrition-associated cholestasis
The Institute of Science and Technology Austria (ISTA) receives €5 million donation for AI research
Study finds link between colorblindness and death from bladder cancer
Tailored treatment approach shows promise for reducing suicide and self-harm risk in teens and young adults
Call for papers: AI in biochar research for sustainable land ecosystems
Methane eating microbes turn a powerful greenhouse gas into green plastics, feed, and fuel
Hidden nitrogen in China’s rice paddies could cut fertilizer use
Texas A&M researchers expose hidden risks of firefighter gear in an effort to improve safety and performance
Wood burning in homes drives dangerous air pollution in winter
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: January 23, 2026
ISSCR statement in response to new NIH policy on research using human fetal tissue (Notice NOT-OD-26-028)
Biologists and engineers follow goopy clues to plant-wilting bacteria
What do rats remember? IU research pushes the boundaries on what animal models can tell us about human memory
Frontiers Science House: did you miss it? Fresh stories from Davos – end of week wrap
Watching forests grow from space
New grounded theory reveals why hybrid delivery systems work the way they do
CDI scientist joins NIH group to improve post-stem cell transplant patient evaluation
Uncovering cancer's hidden oncRNA signatures: From discovery to liquid biopsy
Multiple maternal chronic conditions and risk of severe neonatal morbidity and mortality
Interactive virtual assistant for health promotion among older adults with type 2 diabetes
Ion accumulation in liquid–liquid phase separation regulates biomolecule localization
Hemispheric asymmetry in the genetic overlap between schizophrenia and white matter microstructure
Research Article | Evaluation of ten satellite-based and reanalysis precipitation datasets on a daily basis for Czechia (2001–2021)
Nano-immunotherapy synergizing ferroptosis and STING activation in metastatic bladder cancer
Insilico Medicine receives IND approval from FDA for ISM8969, an AI-empowered potential best-in-class NLRP3 inhibitor
Combined aerobic-resistance exercise: Dual efficacy and efficiency for hepatic steatosis
[Press-News.org] 76 percent of patients on oral JAK1/JAK2 inhibitor plus DMARDS achieve ACR20 response at week 12Baricitinib demonstrates dose-dependent efficacy in active RA